STUDY QUESTION: Can the bioactive lipid sphingosine-1 phosphate (S1P) act as an endothelial barrier-enhancing molecule and, in turn, restore the vascular integrity and homoeostasis in a rat model of ovarian hyperstimulation syndrome (OHSS).
Introduction
Ovarian hyperstimulation syndrome (OHSS) is one the most serious iatrogenic complications of follicular growth and maturation induced by ovulation induction. It is characterized by increased vascular leakage and ovarian enlargement, which cause fast third space fluid shifts from the intravascular compartment (Delvigne and Rozenberg, 2002; Aboulghar and Mansour, 2003) . These shifts are caused by increased vascular permeability in response to stimulation with hCG (Gomez et al., 2010) . The pathophysiology of OHSS is not completely understood, and no specific therapy or prevention is available yet (Rizk and Aboulghar, 1991; Fiedler and Ezcurra, 2012) . It is recognized that this syndrome is triggered by hCG (Gomez et al., 2010) and that the predominant link between hCG and OHSS is the production of angiogenic factors. Several pro-angiogenic factors, including members of the vascular endothelial growth factor A (VEGFA) family, angiopoietins (ANGPTs), transforming growth factors (TGFs), platelet-derived growth factors (PDGFs) and sphingosine-1 phosphate (S1P), have been identified (Hanahan and Folkman, 1996; Neufeld et al., 1999; Carmeliet, 2000; Allende and Proia, 2002; Armulik et al., 2005; Fiedler and Augustin, 2006; Otrock et al., 2007) . One of the main functions of PDGFs and S1P, unlike VEGFA and ANGPTs, is the stabilization of newly developed capillaries (Allende et al., 2003; Hoch and Soriano, 2003; Xiong and Hla, 2014) .
Previously, we have evaluated the involvement of ANGPTs and PDGFs in this syndrome and we have observed that PDGF-B and -D protein levels decrease in ovaries from an OHSS rat model, while ANGPT2 and PDGFR-β levels remain constant (Scotti et al., 2013) . Furthermore, we have shown that ANGPT1 concentration is higher in follicular fluids (FF) from women at risk of developing OHSS than in FF from control patients, whilst the levels of the soluble form of the receptor Tie-2 (sTie-2) remain unchanged. Additionally, inhibition of ANGPT1 in FF from OHSS patients by the use of a neutralizing antibody decreases endothelial cell migration in comparison with untreated FF from OHSS women (Scotti et al., 2013) . Recently, we have observed that the levels of sphingolipid S1P in FF from women at risk of developing OHSS are lower in comparison with FF from women who are not at such risk, while the addition of S1P to the FF restores vascular integrity in an endothelial cell culture (Scotti et al., 2016) . Additionally, we have shown in the same study that in vivo intrabursal administration of S1P in an OHSS rat model decreased ovarian capillary permeability and ovarian expression of VEGF and its receptor KDR. All these findings suggest that the ANGPT, PDGF and S1P systems could be partly responsible for the characteristic increase in ovarian vascular permeability in OHSS. S1P is derived from sphingosine phosphorylation by sphingosine kinase and its degradation can be either mediated by S1P lyase (SPL) or by S1P phosphatases (Le Stunff et al., 2002; Ogawa et al., 2003) . Not only is S1P secreted by activated platelets, but also erythrocytes, mononuclear cells, neutrophils and mastocytes can release this lipid mediator (Yatomi et al., 1995; Yang et al., 1999) . S1P binds to specific cell surface receptors (S1PRs), which comprise a G-protein-coupled receptor family including subtypes S1PR1, S1P2, S1P3, S1P4 and S1P5. S1P is present in blood and plasma and delivered to its receptors by high-density lipoprotein (HDL)-associated apoliprotein M (Singleton et al., 2006) . S1P is a pleiotropic sphingolipid capable of modulating the functions of various cell types (Xiong and Hla, 2014) . In particular, it regulates several physiological responses in vascular cells (Obinata and Hla, 2012) and promotes endothelial cell spreading, vascular maturation/stabilization, and barrier function (Xiong and Hla, 2014) . The alteration of vascular barrier integrity causes serious consequences such as inflammation, edema, haemorrhage and ischaemia. S1P has been proposed as a barrier-enhancing molecule and as a potential candidate for novel and specific therapies for endothelial dysfunction (Sanchez et al., 2003; Gaengel et al., 2012; Jung et al., 2012) . In this regard, Dudek et al. (2004) and Liu et al. (2009) have shown that S1P administration in animal models with acute lung injury decreases vascular hyperpermeability by the enhancement of endothelial junctional integrity (Dudek et al., 2004; Liu et al., 2009) . Furthermore, Curry et al. (2012) have previously shown that exogenous S1P attenuates acute microvascular permeability via receptor S1PR1 and stabilizes the endothelium in rats (Curry et al., 2012) .
The expression of S1PRs (S1PR1, S1P2 and S1P3) has been shown in female reproductive tissues and granulosa cells (Risau, 1997; Kon et al., 1999; Wang et al., 2014) . Also, several authors have previously documented the role of S1P in reproduction. Roth and Hansen (2004) have demonstrated that S1P may improve fertility when developmental competence of the oocytes is compromised (Roth and Hansen, 2004) . Other researchers have proposed S1P as a potential candidate for fertility preservation of female cancer patients (Morita and Tilly, 2000; Li et al., 2014; Meng et al., 2014) . However, there are no studies on the effect of in vivo intrabursal S1P administration on ovarian morphology or vascular development and integrity in a rat model of OHSS. Therefore, the main purpose of this study was to evaluate the effects of local S1P administration on ovarian weight, follicular and luteal development, formation of cystic structures, steroidogenesis, endothelial and periendothelial area (pericytes and smooth muscle cells), and on adherens and tight junction protein expression in ovaries from an OHSS rat model stimulated by equine chorionic gonadotropin (eCG), and hCG. In this model, we assessed the effect of S1P administration on S1PR1 protein expression in ovaries. Additionally, in this model we evaluated the effect of S1P on uterine morphology.
Materials and Methods

Ethical approval
All procedures were approved by the ethics committee of the IByME (CE-018-2/2012) and conducted according to the guide for the care and use of laboratory animals of the National Institute of Health (USA).
Animal model and experimental design
Rats were housed and cared at the Instituto de Biología y Medicina Experimental (IByME), Buenos Aires, Argentina. Immature female SpragueDawley rats (21-23 days old) from our colony (n = 6/group for each treatment) were allowed food and water ad libitum and kept at room temperature (21-23°C) on a 12 L:12D cycle. We used an animal model that develops OHSS in immature Sprague-Dawley rats (21-23 days, 60-80 g), as described by Kitajima et al. (2004 Kitajima et al. ( , 2006 . The control group (n = 6) was injected with 10 IU eCG and with 10 IU hCG 48 h later. The OHSS group (n = 6) was injected with 50 IU eCG for four consecutive days, followed by 25 IU of hCG. The OHSS + S1P group (n = 6) received the same doses of eCG and hCG as the OHSS group and was also treated with S1P. To administrate S1P on the day of hCG injection, the animals were anesthetized with ketamine HCl (70 mg/kg; Holliday-Scott S.A., Buenos Aires, Argentina) and xylazine (5 mg/kg; König Laboratories, Buenos Aires, Argentina) and the ovaries were exteriorized through an incision made in the dorsal lumbar region. The OHSS + S1P group received 5 μl S1P (1 mM) (Sigma Aldrich, St. Louis, MO, USA) under the bursa of both ovaries (Hernandez et al., 2009) , whereas the other groups received the S1P vehicle (0.8% Tween-80; 2.5% ETOH; 5% polyethylene glycol).
Rats were killed by decapitation 48 h after the hCG injection for ovary and blood collection. The ovaries were removed and cleaned of adhering tissue in culture medium, weighed, and used for subsequent assays. The serum was used for hormone assays. One ovary from each rat (n = 6) was used for Western blotting and the other for immunohistochemical analysis.
Steroid hormone assay
Serum steroid concentrations were measured by radioimmunoassay (RIA) (n = 6 rats/group) (Irusta et al., 2003; Irusta et al., 2007) . Progesterone (P 4 ) was measured by using specific antibodies supplied by Dr G.D. Niswender (Animal Reproduction and Biotechnology Laboratory, Colorado State University, Fort Collins, CO, USA). Under these conditions, the intra-and inter-assay variations for P 4 were 8.0 and 14.2%, respectively. The values are expressed per ml of serum.
Ovarian and endometrium morphology
Ovaries and uterine horns were extracted from the different experimental groups and immediately fixed in Bouin solution for 12 h. Histological sections were made for haematoxylin-eosin (H&E) staining. Ovarian sections (5 μm) were mounted at 50-μm intervals onto microscope slides to prevent counting the same structure twice, according to the method described by Woodruff et al. (Woodruff et al., 1988) . Preantral follicles, antral follicles, atretic follicles, corpora lutea (CL) and cystic structures were counted in six ovarian sections from each ovary (n = 6 ovaries/ group) and expressed as structure percentage per ovary. The total number of ovarian structures was defined as 100%. Cysts were defined as structures with presence of oocytes surrounded by luteal cells, remaining granulosa cells and red blood cells (Scotti et al., 2014a) . A set of uterine sections was stained with H&E and examined microscopically by an experienced gynecologic pathologist, who was blinded to the group assignment.
Histochemistry and immunohistochemistry in luteal tissues
Tissue sections were deparaffinized in xylene and rehydrated by graduated ethanol washes. Endogenous peroxidase activity was blocked with hydrogen peroxide in PBS and nonspecific binding was blocked with 2% bovine serum albumin (BSA) overnight at 4°C. Sections were incubated with biotinylated lectin BS-1 (from Bandeiraea simplicifolia, 20 μg/ml, Vector Laboratories, Burlingame, CA, USA) or α-SMA (smooth muscle actin) 1/250 (ab18147 Abcam, Cambridge, MA, USA) overnight at 4°C. Lectin BS-1 has demonstrated to be a constitutive endothelial cell marker staining endothelial cells at the different developmental stages of CL with similar intensity (Augustin et al., 1995; Redmer et al., 2001; Cherry et al., 2008) . After washing, slides were incubated with biotinylated anti-mouse IgG (except in the case of lectin BS-1) and afterwards with avidin-biotinylated horseradish peroxidase Complex (Vectastain ABC system from Vector Laboratories) for 30 min. Protein expression was visualized with diaminobenzidine (DAB) staining. After stopping the reaction with distilled water, slides were stained with haematoxylin, dehydrated and mounted (Canada Balsam Synthetic, Biopack, Argentina). Negative controls were obtained in absence of primary antibody.
The images were digitized with a camera (Nikon, Melville, NY, USA) mounted on a conventional light microscope (Nikon), using a magnification of ×40. Three sections per ovary were analysed (six ovaries/group) and at least four corpora lutea were photographed per section. Images were converted to TIFF format for analysis and processed using Image Pro-Plus 3.0 ® (Media Cybernetics, Silver Spring, MA, USA). Endothelial and periendothelial cell areas were determined by thresholding each lectin BS-1-or α-SMA-positive stained areas, which were then normalized to the total area of the analysed corpus luteum.
Western blot
Ovaries were removed, placed on ice and resuspended in five volumes of lysis buffer (20 mM Tris-HCl pH 8, 137 mM NaCl, 1% Nonidet P-40 and 10% glycerol) supplemented with protease inhibitors (0.5 mM PMSF, 0.025 mM N-CBZ-L-phenylalanine chloromethyl ketone, 0.025 mM N-p-tosyl-lysine chloromethyl ketone and 0.025 mM L-1-tosylamide-2-phenyl-ethylchloromethyl ketone) and homogenized with an UltraTurrax homogenizer (IKA Werk, Breisgau, Germany). Samples were centrifuged at 4°C for 10 min at 10 000 × g and the resulting pellets were discarded. Protein concentration in the supernatant was measured by the Bradford assay. After boiling for 5 min, 40 μg of protein was applied to a 12% SDS-polyacrylamide gel and electrophoresis was performed at 25 mA for 1.5 h. The resolved proteins were transferred onto nitrocellulose membranes for 2 h. The blot was then incubated in blocking buffer (5% nonfat milk, 0.05% tween-20 in 20 mM TBS pH 8.0) for 1 h at room temperature and incubated overnight at 4°C with appropriate primary antibodies: StAR 1/1000 was donated by Dr D. M. Stocco (Texas Tech University Health Sciences Center); P450scc 1/2000 was donated by Dr Anita Payne (Stanford University Medical Center, Stanford, CA, USA); S1PR1 (ab125074) was from Abcam (Cambridge, USA), 3βHSD 1/1000 (sc-30 820), VE-cadherin 1/100 (sc-9989), N-cadherin 1/250 (sc-7939) and Nectin-2 1/200 (sc-373 715) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); and Claudin-5 1/1000 (35-2500), occludin: 1/1000 (71-1500) were from Invitrogen Corp. (Carlsbad, CA, USA), β-actin 1/10 000 (4967) and GAPDH 1/10 000 (14C10) were from Cell Signaling Technology, INC (Baverly, MA, USA). The blot was then incubated with anti-mouse or anti-rabbit secondary antibodies conjugated with horseradish peroxidase (1:1000) and signal was detected by chemiluminescence. The protein levels were analysed by densitometry using Scion Image for Windows (Scion Corporation, Worman's Mill, CT, USA). Optical density data are expressed as arbitrary units ± SEM. The density in each band was normalized to the density of the β-actin or GAPDH band, which were used as an internal control.
Data analysis
The results are expressed as the mean ± SEM and the significant differences between groups were determined using analysis of variance (ANOVA), followed by Tukey's test. P < 0.05 were considered statistically significant. All samples were tested for normality before ANOVA. Data were statistically analysed using Prism v5.0.
Results
Effect of S1P on ovarian weight and progesterone (P 4 ) concentration in the rat model of OHSS
The effects of S1P on ovarian weight and P 4 serum concentration are summarized in Table I . The ovarian weight in the OHSS group was higher compared to the control group (P < 0.001). S1P administration reduced the ovarian weight observed in the OHSS group without treatment (P < 0.05). Serum P 4 concentration in the OHSS group was higher than that in the control group (P < 0.001). S1P treatment decreased the concentration of serum P 4 compared with the untreated OHSS group (P < 0.001).
Effect of S1P on ovarian morphology and steroidogenic enzyme expression in the rat model of OHSS
The percentage of antral follicles in the OHSS group was lower than that in the control group. In the OHSS + S1P group, the percentage of antral follicles increased compared to the OHSS group without treatment (P < 0.05) (Fig. 1B) . However, no significant differences were observed in the percentage of preantral or atretic follicles among the three experimental groups (Fig. 1A and C) . The percentage of CL in the OHSS group increased significantly compared with that in the control group (P < 0.05) (Fig. 1D) . Local administration of S1P reduced the percentage of CL (P < 0.01) and cystic structures in comparison with the untreated OHSS group (P < 0.05) ( Fig. 1D and E) .
To evaluate the effect of S1P on steroidogenesis in the OHSS rat model, we studied the expression of 3βHSD, P450scc and StAR. The levels of these enzymes in the OHSS group were higher than those in the control group (3βHSD: P < 0.05; P450scc: P < 0.01; StAR: P < 0.05) (Fig. 2) . S1P administration had no effect on the expression levels of 3βHSD or P450scc in OHSS rat ovaries ( Fig. 2A and B) , but decreased StAR levels compared to the untreated OHSS group (P < 0.05) (Fig. 2C) .
Effect of S1P on luteal vascular development in the rat model of OHSS To evaluate whether S1P treatment causes changes on endothelial cells present in corpora lutea, we stained ovarian sections for lectin BS-1. The endothelial cell area in the OHSS group was higher than that in the control group (P < 0.001), while S1P administration decreased the endothelial cell area compared to OHSS group (P < 0.001) (Fig. 3A) .
Also, we evaluated luteal vascular stability in ovarian sections immunostained with α-SMA antibody. The periendothelial cell area in the OHSS group was lower than that in the control group (P < 0.001), while S1P increased the periendothelial cell area compared to the OHSS group without treatment (P < 0.05) (Fig. 3B) .
Effect of S1P on the expression of endothelial cell-to-cell junction proteins in the rat model of OHSS
The levels of N-cadherin and VE-cadherin were lower in the OHSS group than in the control group (P < 0.05). Local administration of S1P restored the levels of these proteins to control values ( Fig. 4A and B) .
The levels of the tight junction proteins claudin-5, occludin and Nectin-2 were lower in the OHSS group in comparison with the control group (claudin-5: P < 0.01; occludin: P < 0.001; Nectin-2: P < 0.05). S1P treatment increased the levels of claudin-5 and occludin compared to those in the OHSS group (P < 0.05), whereas the levels of Nectin-2 remained unchanged ( Fig. 4C-E) .
Effect of S1P on the expression of S1PR1 in the rat model of OHSS
The ovarian levels of S1PR1 in the OHSS group were similar to those in the control group. In the OHSS + S1P group, the levels of S1PR1 increased compared to those of the OHSS group (P < 0.01) (Fig. 5) .
Effect of S1P on uterine morphology in the rat model of OHSS
The endometrium from the control group showed a few residual glands surrounded by an atrophic, somewhat fibrotic stroma. The epithelium was low cuboidal or columnar with almost no mitotic figures (Fig. 6) .
The endometrium of the OHSS and S1P-treated OHSS groups showed a columnar surface epithelium with slight pseudostratification and small, round and regular glands. In addition, endometrial stroma showed no edema but occasional mitotic figures, and small and Note: Data are expressed as mean ± SEM; n = 6 rats/group. Letters indicate a significant statistical difference between groups by one-way ANOVA, followed by Tukey's multiple comparison test. Ovarian weight: a vs b P < 0.001; a vs c P < 0.01; b vs c P < 0.05. Serum progesterone: a vs b P < 0.001.
regularly distributed blood vessels. No histological differences were found in endometrium between OHSS and S1P-treated OHSS animals.
Discussion
The main clinical characteristics of OHSS are ovarian enlargement, with luteal and haemorrhagic cysts, and increased vascular permeability (Golan et al., 1989; Gomez et al., 2010) . Previously, we and other authors have demonstrated that VEGF, ANGPTs, PDGFs could be mediators in the development of OHSS (Artini et al., 1998; Pellicer et al., 1999; Scotti et al., 2013 Scotti et al., , 2014a . Recently, we have shown that S1P levels are lower in FF from patients at risk of OHSS and that treatment with S1P may decrease vascular permeability in these patients (Scotti et al., 2016 ).
In the current study, we present evidence for the first time that S1P intrabursal administration in vivo affects ovarian weight, follicular and luteal development, formation of cystic structures and steroidogenesis Figure 1 Effect of S1P treatment on preantral follicles, antral follicles, atretic follicles, corpora lutea and cysts from the rat OHSS model. The graphs show the percentage of each structure in H&E-stained ovarian sections. Different letters indicate significant differences. (A) % preantral follicles (P > 0.05). (B) % antral follicles (Control vs OHSS P < 0.05; OHSS vs OHSS + S1P P < 0.05). (C) % atretic follicles (P > 0.05). (D) % corpora lutea (Control vs OHSS P < 0.05; OHSS vs OHSS + S1P P < 0.01). (E) % cysts (Control vs OHSS P < 0.001; Control vs OHSS + S1P P < 0.01; OHSS vs OHSS + S1P P < 0.05). Data are expressed as the mean ± SEM. Results were obtained from three experiments, using six rats per group. Figure 2 Effect of S1P treatment on steroidogenic enzymes levels in ovaries from the rat OHSS model. The levels of proteins in ovarian protein extracts were measured by Western Blotting. The density in each band was normalized to the density of the β-actin or GAPDH band. The lower panels show a representative blot for each protein analyzed. Different letters indicate significant differences. (A) 3βHSD (Control vs OHSS P < 0.05; Control vs OHSS + S1P P < 0.05), (B) P450scc (Control vs OHSS P < 0.01; Control vs OHSS + S1P P < 0.01) and (C) StAR (Control vs OHSS P < 0.05; OHSS vs OHSS + S1P P < 0.05). Data are expressed as the mean ± SEM. Results were obtained from three experiments, using six rats per group.
in ovaries from a rat OHSS model. Additionally, we observed that local administration of this sphingolipid causes a decrease in the endothelial area, an increase in both the periendothelial area and N-cadherin, VEcadherin, claudin-5 and S1PR1 receptor protein levels in the ovaries of the above-mentioned model.
In humans, OHSS generates the formation of multiple CL and the increase of VEGF levels (Navot et al., 1992) . Our study is the first to demonstrate that administration of S1P in vivo in ovaries from OHSS rats affects luteal development, delays folliculogenesis and leads to a lower percentage of CL. These results suggest that, as S1P decreases Figure 3 Effect of S1P treatment on ovarian vessels-Corpora lutea from the rat OHSS model. (A) Lectin BS-1 staining in Control, OHSS, and S1P-treated OHSS rats. Graph: Quantification of endothelial cell area in Corpora lutea sections stained in the three groups analyzed. Different letters indicate significant differences (Control vs OHSS P < 0.001; OHSS vs OHSS + S1P P < 0001). The photographs show representative histological sections of control, OHSS and OHSS + S1P Corpora lutea stained with lectin BS-1. Scale bars, 100 μm. Three sections per ovary were analysed (six ovaries/ group) and at least four corpora lutea were photographed per section. (B) Immunostaining of periendothelial cells with anti-smooth muscle cell α-actin antibody in control, OHSS, and S1P-treated OHSS rats. Graph: Quantification of periendothelial cell area in Corpora lutea in the three groups analyzed. (Control vs OHSS P < 0.001; OHSS vs OHSS + S1P P < 0.05; OHSS + S1P vs Control P < 0.01). The photographs show representative histological sections of control, OHSS, and S1P-treated OHSS rat ovaries stained with anti-smooth muscle cell α-actin antibody. Scale bars, 100 μm. Three sections per ovary were analysed (six ovaries/group) and at least four corpora lutea were photographed per section. the presence of CL, which secrete several angiogenic factors that in turn favour an altered angiogenesis, this lipid metabolite is also likely to ameliorate the vascular permeability observed in OHSS. The decrease in CL and cystic structures in the S1P-treated ovaries is consistent with the decrease in serum P 4 and ovarian weight observed. It is known that the transport of cholesterol from the cytoplasm to the inner mitochondrial membrane, mediated by the StAR protein, is the limiting step in progesterone (P 4 ) synthesis. Therefore, the diminished expression of StAR, as demonstrated by Western blot, could be partly responsible for the decrease in serum P 4 in the S1P-treated OHSS rats. These results are consistent with those obtained by other authors such as Budnik and Brunswig-Spickenheier (2005) , who have shown that S1P suppresses P 4 synthesis in luteal cells and Leydig tumour cells stimulated with luteotropic hormone or a cAMP analog (Budnik and Brunswig-Spickenheier, 2005) . It is worth noting that S1P did not affect ovarian expression of P450scc or 3βHSD, which are critical for biosynthesis of steroid hormones.
CL are highly vascularized structures, whose vascular development exceeds that of most tumours (Reynolds et al., 2000) . In this study, the in vivo administration of S1P may have altered the formation and function of CL by preventing angiogenesis in OHSS. The decrease in luteal endothelial cell area after S1P administration suggests that the sphingolipid caused a decrease in the number of endothelial cells, and thus a Figure 4 Effect of S1P treatment on the expression of adherens and tight junction proteins in ovaries from the rat OHSS model. The graphs show the densitometric analysis for adherens (N-cadherin and VE-cadherin) and tight (claudin-5, occludin, Nectin-2) junction proteins in ovarian protein extracts. (A) N-cadherin (Control vs OHSS P < 0.05; OHSS vs OHSS + S1P P < 0.05), (B) VE-cadherin (Control vs OHSS P < 0.05; OHSS vs OHSS + S1P P < 0.01), (C) claudin-5 (Control vs OHSS P < 0.01; OHSS vs OHSS + S1P P < 0.05) (D) occludin (Control vs OHSS P < 0.001; Control vs OHSS + S1P P < 0.05; OHSS vs OHSS + S1P P < 0.05) and (E) Nectin-2 (Control vs OHSS P < 0.05; Control vs OHSS + S1P P < 0.05). The density of each band was normalized to the density of the β-actin or GAPDH band. The lower panels show a representative blot for each protein analyzed. Different letters indicate significant differences. Data are expressed as the mean ± SEM. Results were obtained from three experiments, using six rats per group. Figure 5 Effect of S1P treatment on the expression of S1P receptor 1 (S1PR1) in ovaries from the rat OHSS model. Densitometric quantification of S1PR1 levels in ovarian protein extracts. The density of each band was normalized to the density of the GAPDH band. The lower panels show a representative blot for the protein analyzed. Different letters indicate significant differences (Control vs OHSS + S1P P < 0.01; OHSS vs OHSS + S1P P < 0.01). Data are expressed as the mean ± SEM. Results were obtained from three experiments, using six rats per group. decrease in the luteal microvasculature that likely contributed to the decrease in serum P 4 concentrations. Pericyte coverage induces vessel maturation by resolving angiogenic signals and reducing endothelial proliferation. Thus, the recruitment of periendothelial cells and the deposition of basal membranes represent crucial steps to achieve vascular maturation (Potente et al., 2011) . In our study, S1P was able to increase the recruitment of pericytes and smooth muscle cells, enhancing pericyte-endothelium interaction and, in turn, improving luteal vessel stability in OHSS. It is worth noting that the breakdown of the S1P signalling system results in pathological hyperpermeability such as acute lung injury, anaphylaxis and inflammation (Olivera et al., 2003; Peng et al., 2004) .
Controlled dynamic changes in the localization and expression of adhesion molecules are essential in the ovary (Groten et al., 2006; Rodewald et al., 2007) . This includes regulation of adherens and tight junctions (AJ and TJ), which are key components of intercellular junctions (Dejana, 2004; Schneeberger and Lynch, 2004 ). An increase in endothelial permeability is generally accompanied by reorganization of junctional proteins, inducing a transient opening of the endothelial junctions and an increment in vascular permeability (Bazzoni and Dejana, 2004; Dejana, 2004; Walz et al., 2005) . TJ proteins, which are composed of at least three different families of transmembrane proteins (claudins, occludins and junction adhesion molecules), represent a barrier to molecule diffusion from the vessel lumen to the tissue parenchyma (Groten et al., 2006) , whereas AJ proteins involve transmembrane proteins belonging to the cadherin family. Thus, we propose that TJ and AJ proteins are downstream targets of S1P in vascular cells of ovaries from animals with OHSS. Since VE-cadherin is the main structural protein of AJ in endothelial cells (Mehta et al., 2005) , we decided to study the levels of this protein in the OHSS rat model. We and other authors showed the importance of this cadherin in the development of OHSS (Villasante et al., 2007; Scotti et al., 2014a) . We have previously observed that VEcadherin levels decrease significantly in endothelial cells incubated with FF from OHSS patients compared to control patients. In the present study, we observed that S1P is able to restore the levels of VE-cadherin, contributing to the sealing of the intercellular space and reducing vascular permeability in the ovary. These results are consistent with recently obtained studies in our laboratory, as we found that S1P addition increased VE-cadherin expression and reduced VEGF expression in endothelial cells compared to FF from patients at risk of OHSS without the sphingolipid (Scotti et al., 2016) . Regarding this point, Gaengel et al. (2012) have studied the communication between the VEGF and S1P systems and demonstrated that when co-stimulating human umbilical vein endothelial cells (HUVEC) with VEGF and S1P, VE-cadherin remained stable in endothelial junctions and was insensitive to the internalization induced by VEGF (Gaengel et al., 2012) . Additionally, Lee et al. (1999) have demonstrated that S1P increases the VE-cadherin and β-catenin levels and, in turn, enhances AJ assembly in confluent HUVEC (Lee et al., 1999) . Furthermore, Krump-Konvalinkova et al. (2005) have shown that S1PR1 silencing decreases the expression of platelet-endothelial cell adhesion molecule-1 (PECAM) and VE-cadherin human endothelial cell lines (Krump-Konvalinkova et al., 2005) .
Besides VE-cadherin, N-cadherin also regulates vascular stability since it mediates pericyte adhesion to endothelial cells, enhancing vessel maturation and stabilization (Volk and Geiger, 1984; Tillet et al., 2005) . In the present study, S1P restored the levels of N-cadherin suggesting that, in OHSS, S1P improves the endothelial-pericyte interaction mediated by this cadherin, contributing to vessel maturation and endothelial barrier integrity. This supports previous data from our laboratory, where we have shown that S1P addition increased N-cadherin levels in endothelial cells compared to FF from patients at risk of OHSS without the sphingolipid (Scotti et al., 2016) . Furthermore, Paik et al. (2004) have shown that the inhibition of N-cadherin affects vascular stabilization in vitro and in vivo, suggesting a specific involvement of S1P in N-cadherin-induced pericyte attachment (Paik et al., 2004) .
The nectin system has been described as a novel modulator of AJ and TJ, and provides the first scaffold for the formation of these junctions (Niessen, 2007) . Based on this information, we analysed the expression in the rat OHSS model of claudin-5 and occludin (TJ proteins), and also of nectin-2, the only member of the nectin system that is expressed in the endothelium of CL (Herr et al., 2015) . S1P was able to restore the decreased levels of claudin-5, occludin and nectin 2, contributing to the formation of TJ and ovarian vascular stability. Taking together these results suggests that S1P upregulates VEcadherin, N-cadherin, claudin-5 and occludin and consequently reduces vascular permeability in OHSS. Accordingly, S1P improves the assembly of AJ and assists in the formation of TJ.
Moreover, S1P is able to enhance endothelial maturation through its receptor, S1PR1, by promoting Rac1 activation and AJ assembly (Garcia et al., 2001 ). Thus, we evaluated S1PR1 expression in the Figure 6 Effect of S1P treatment on uterine morphology from the rat OHSS model. H&E stained sections show representative histological fields of Control, OHSS and OHSS + S1P uterus. The dotted lines indicate the thickness of the endometrium. The endometrium from the control group showed a few residual glands with a covering epithelium that is low cuboidal to columnar. On the other hand, the endometrium of the OHSS and S1P-treated OHSS group, showed a tall columnar surface epithelium with pseudostratification and signs of an increased turnover, scattered glands are seen within the thickness of the endometrium. Scale bars, 50 μm. Insets in all panels show images at higher magnification of the endometrial epithelium. Scales bars, 5 μm. OHSS model. S1P was able to upregulate the expression of its own receptor, enhancing vascular integrity and, in turn, avoiding the aberrant angiogenic responses observed in OHSS. The precise mechanism by which the sphingolipid increases expression of its own receptor is currently unknown. These findings are in line with the observations by Gaengel et al. (2012) , who demonstrated that S1PR1 signalling inhibits endothelial hyper-sprouting through stabilization of VE-cadherin and through inhibition of VEGFR2 phosphorylation (Gaengel et al., 2012) .
We decided to evaluate possible side-effects of S1P treatment in other vascularized organs, such as the uterus. We did not observe any change in endometrial morphology after S1P treatment in the OHSS model.
In summary, our study shows that local S1P administration decreases the percentage of CL and cystic structures, serum P 4 concentrations, endothelial cell area and StAR protein expression in ovaries from OHSS rats, and increases the percentage of antral follicles, periendothelial area, and S1PR1, AJ and TJ protein levels in OHSS rats.
Therefore, local administration of S1P decreased the vascular permeability and angiogenesis in the OHSS group. These effects would be directly mediated by the decrease in the percentage of the CL and in blood vessel development, and by the increase in vascular stability in the CL. Our findings would indicate for the first time that S1P acts in the rat OHSS model as an endothelial barrier-enhancing factor, restoring the vascular integrity and homoeostasis in OHSS. S1P administration may therefore prevent the early onset of OHSS and decrease its severity. More studies on the regulation of endothelial cell barrier function by the bioactive lipid S1P in reproductive pathological processes and its therapeutic application are required.
